<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>29384127</identifier>
<setSpec>1665-1146</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>González Ortiz, Beatriz</dc:author>
<dc:author>Hernández Mondragón, Oscar</dc:author>
<dc:author>Tapia Monge, Dora María</dc:author>
<dc:author>Reyes Cerecedo, Alicia</dc:author>
<dc:description xml:lang="en">BACKGROUND Hemospray® is a new device for endoscopic hemostasis used for non-variceal gastrointestinal bleeding. It enables hemostasis and platelet activation by increasing the concentration of clotting factors and forming a mechanical barrier on the wall of a bleeding vessel creating a mechanical plug at the site of bleeding. Within the main indications for use are: injuries with difficult endoscopic access, massive gastrointestinal bleeding, multiple bleeding sites, modification of the anatomy by previous endoscopic therapy, presence of coagulopathy, difficulty in having direct visualization or when it is impossible to have contact with the bleeding lesion. However, its use in children has not been approved yet by the FDA. There is a case report of an 11-month-old patient successfully treated with Hemospray® for non-variceal gastrointestinal bleeding. CLINICAL CASE We report the case of a 2-year-old female with acute liver failure and primary biliary cirrhosis with portal hypertension and bleeding after sclerotherapy. We analyzed the case to support new therapies for massive bleeding control in post-sclerotherapy esophageal ulcers. CONCLUSIONS The application showed to be safe without side effects. Using Hemospray® is an effective alternative in controlling gastrointestinal bleeding.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:subject>Sangrado no variceal</dc:subject>
<dc:subject>Úlcera post-escleroterapia</dc:subject>
<dc:subject>No variceal bleeding</dc:subject>
<dc:subject>Niños</dc:subject>
<dc:subject>Hemospray®</dc:subject>
<dc:subject>Children</dc:subject>
<dc:subject>Post-sclerotherapy esophageal ulcer</dc:subject>
<dc:date>2016 Sep - Oct </dc:date>
<dc:title xml:lang="es">Uso de Hemospray® en sangrado post-escleroterapia.</dc:title>
<dc:title xml:lang="en">[Use of Hemospray® in post-sclerotherapy bleeding].</dc:title>
<dc:publisher>Boletin medico del Hospital Infantil de Mexico</dc:publisher>
</metadata>
</record>
</pubmed-document>
